Toxicity and outcome of children with treatment related acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 50, Issue 1, 2008, Pages 17-23

  Tabori, Uri ^a   Revah, Giselle ^a   Nathan, Paul C ^a   Strahm, Brigitte ^a   Rachlis, Alisa ^a   Shago, Mary ^a   Grant, Ronald ^a   Doyle, John ^a   Malkin, David ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Child; Toxicity; Treatment related leukemia

Indexed keywords

ANTHRACYCLINE; CYTARABINE; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 36849078783     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21157     Document Type: Article

References (35)

1. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002;2:124-132.
2. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-629.
3. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-751.
4. Meadows AT. Risk factors for second malignant neoplasms: Report from the Late Effects Study Group. Bull Cancer 1988;75:125-130.
5. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 1987;79:1213-1220.
6. Wong FL, Boice JD, Jr., Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262-1267.
7. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 2003;21:1074-1081.
8. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992;19:47-84.
9. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003;102:43-52.
10. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-1687.
11. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-577.
12. Barnard DR, Woods WG. Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer - an update. Leuk Lymphoma 2005;46:651-663.
13. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 2000;95:1588-1593.
14. Kushner BH, Heller G, Cheung NK, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol 1998;16:3016-3020.
15. Sandoval C, Pui CH, Bowman LC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993;11:1039-1045.
16. Kern W, Haferlach T, Schnittger S, et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004;22:2510-2511.
17. Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366-2378.
18. Pagano L, Pulsoni A, Vignetti M, et al. Secondary acute myeloid leukaemia: Results of conventional treatments. Experience of GIMEMA trials. Ann Oncol 2005;16:228-233.
19. Pulsoni A, Pagano L. Treatment of secondary acute myeloid leukemia. J Clin Oncol 2005;23:926-927.
20. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-125.
21. Armendariz H, Barbieri MA, Freigeiro D, et al. Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials. Leukemia 2005;19:2139-2142.
22. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030-2042.
23. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005;19:2130-2138.
24. Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group - report of three consecutive trials. Leukemia 2005;19:2090-2100.
25. Pession A, Rondelli R, Basso G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 2005;19:2043-2053.
26. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005;19:2101-2116.
27. Ribeiro RC, Razzouk BI, Pounds S, et al. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia 2005;19:2125-2129.
28. Preisler HD, Early AP, Raza A, et al. Therapy of secondary acute nonlymphocytic leukemia with cytarabine. N Engl J Med 1983;308:21-23.
29. Rowe JM. Therapy of secondary leukemia. Leukemia 2002;16:748-750.
30. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
31. Suciu SZR, Mandelli F, de Witte T, et al. Allogeneic vs autologous stem cell transplantation according to cytogenetic features in AML patients 45 years old in first CR: Results of the EORTC-GIMEMA AML-10 Trial. Blood 2001;98:481.
32. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62.
33. Creutzig U, Reinhardt D. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? A European view. Br J Haematol 2002;118:365-377.
34. Barnard DR, Lange B, Alonzo TA, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: Comparison with primary presentation. Blood 2002;100:427-434.
35. Wells RJ, Adams MT, Alonzo TA, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 2003;21:2940-2947.